Search

IMI2 Call for Research Proposals

The indicative budget for this topic is 40 million Euro, half of which by way of an in kind contribution from Industry Consortium EFPIA (European Federation of Pharmaceutical Industries and Associations) companies.

Read more

Welcome to the EHA2025 Sponsor Program

On this page, you can browse and/or download the interactive EHA2025 Sponsor Program. If the EHA2025 Sponsor Program does not display correctly, please click here or download the file.  

Read more

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

Evaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER

Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.

Read more

Report Drug Shortages to EHA

In an effort to mitigate shortages of hematologic drugs in Europe, EHA is collecting and compiling reports of shortages. Are you experiencing, or foreseeing drug shortages in your clinical practice?

Please report those to drugshortage@ehaweb. org.

Read more